For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Epizyme, Inc.

USPTO Granted Patents = 158

CIPO Patents = 10

EPO Patents = 45

Trademarks = 7

Forward Citations = 2,298

Loading Chart...

Loading Chart...

67 inventors (with patents filed for the assignee):

Richard Chesworth (85 out of 107 patents)

Kevin Wayne Kuntz (73 out of 84 patents)

Kenneth William Duncan (46 out of 50 patents)

4. Lorna Helen Mitchell (33 out of 33 patents)

5. Gideon Shapiro (33 out of 74 patents)

6. Heike Keilhack (32 out of 32 patents)

7. Sarah Kathleen Knutson (31 out of 31 patents)

8. Lei Jin (27 out of 29 patents)

9. Michael John Munchhof (26 out of 53 patents)

10. Paula Ann Boriack-Sjodin (25 out of 28 patents)

11. Edward James Olhava (21 out of 45 patents)

12. Masashi Seki (19 out of 19 patents)

13. John Emmerson Campbell (18 out of 40 patents)

14. Oscar Miguel Moradei (17 out of 32 patents)

15. Christine Klaus (16 out of 16 patents)

Core Competencies:

EZH2 Inhibitors

Histone Methyltransferase

Cancer Treatment

Combination Therapy

Aryl Compounds

Substituted Benzene Compounds

PRMT5 Inhibitors

CARM1 Inhibitors

MYST Family Inhibitors

Arginine Methyltransferase

Substituted Indoles

Purine Compounds

158 patents: Sort by Forward Citations

1. 12251386 - Salt form of a human histone methyltransferase EZH2 inhibitor (2025-03-18),

2. 12168016 - Aryl-OR heteroaryl-substituted benzene compounds (2024-12-17),

3. 12168015 - Aryl-or heteroaryl-substituted benzene compounds (2024-12-17),

4. 12168014 - Method for treating cancer (2024-12-17),

5. 12162865 - Methods of treating cancer (2024-12-10),

6. 12161645 - Aryl-or heteroaryl-substituted benzene compounds (2024-12-10),

7. 12116358 - Substituted indoles and methods of use thereof (2024-10-15),

8. 11952572 - Methods of treating cancer by inhibiting SETD2 (2024-04-09),

9. 11951109 - EZH2 inhibitors for treating lymphoma (2024-04-09),

10. 11951108 - Combination therapy for treating cancer (2024-04-09),

11. 11834455 - Carm1 inhibitors and uses thereof (2023-12-05),

12. 11786533 - Use of EZH2 inhibitors for treating cancer (2023-10-17),

13. 11753433 - Methods of synthesizing substituted purine compounds (2023-09-12),

14. 11685732 - MYST family histone acetyltransferase inhibitors (2023-06-27),

15. 11672800 - Combination therapies with EHMT2 inhibitors (2023-06-13),

Epizyme, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel epigenetic therapies for cancer and other serious diseases. Epizyme's proprietary platform enables the identification and development of small molecule inhibitors of chromatin modifying proteins (CMPs), which regulate gene expression. The company aims to improve patient outcomes by targeting the underlying genetic abnormalities driving diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

158 Patents

#17 in Cambridge, MA

#133 in Massachusetts

#2,433 in US

#5,076 in the World

Cambridge, MA, United States of America

Epizyme, Inc.

Forward Citations = 2,298

67 inventors:

Richard Chesworth (85 out of 107 patents)

Kevin Wayne Kuntz (73 out of 84 patents)

Kenneth William Duncan (46 out of 50 patents)

4. Lorna Helen Mitchell (33 out of 33 patents)

5. Gideon Shapiro (33 out of 74 patents)

Please report any incorrect information to support@idiyas.com

Loading…